1719 related articles for article (PubMed ID: 15780432)
21. GPR119 regulates murine glucose homeostasis through incretin receptor-dependent and independent mechanisms.
Flock G; Holland D; Seino Y; Drucker DJ
Endocrinology; 2011 Feb; 152(2):374-83. PubMed ID: 21068156
[TBL] [Abstract][Full Text] [Related]
22. Enteroinsular signaling: perspectives on the role of the gastrointestinal hormones glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide in normal and abnormal glucose metabolism.
Vahl T; D'Alessio D
Curr Opin Clin Nutr Metab Care; 2003 Jul; 6(4):461-8. PubMed ID: 12806222
[TBL] [Abstract][Full Text] [Related]
23. Genetic determinants of circulating GIP and GLP-1 concentrations.
Almgren P; Lindqvist A; Krus U; Hakaste L; Ottosson-Laakso E; Asplund O; Sonestedt E; Prasad RB; Laurila E; Orho-Melander M; Melander O; Tuomi T; Holst JJ; Nilsson PM; Wierup N; Groop L; Ahlqvist E
JCI Insight; 2017 Nov; 2(21):. PubMed ID: 29093273
[TBL] [Abstract][Full Text] [Related]
24. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice.
Pederson RA; Satkunarajah M; McIntosh CH; Scrocchi LA; Flamez D; Schuit F; Drucker DJ; Wheeler MB
Diabetes; 1998 Jul; 47(7):1046-52. PubMed ID: 9648827
[TBL] [Abstract][Full Text] [Related]
25. The incretin system and its role in type 2 diabetes mellitus.
Holst JJ; Vilsbøll T; Deacon CF
Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605
[TBL] [Abstract][Full Text] [Related]
26. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
Diamant M; Bunck MC; Heine RJ
Ned Tijdschr Geneeskd; 2004 Sep; 148(39):1912-7. PubMed ID: 15495988
[TBL] [Abstract][Full Text] [Related]
27. Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling.
Scrocchi LA; Marshall BA; Cook SM; Brubaker PL; Drucker DJ
Diabetes; 1998 Apr; 47(4):632-9. PubMed ID: 9568697
[TBL] [Abstract][Full Text] [Related]
28. Gut peptides in the treatment of diabetes mellitus.
Vahl TP; D'Alessio DA
Expert Opin Investig Drugs; 2004 Mar; 13(3):177-88. PubMed ID: 15013938
[TBL] [Abstract][Full Text] [Related]
29. Incretin hormones--an update.
Holst JJ; Orskov C
Scand J Clin Lab Invest Suppl; 2001; 234():75-85. PubMed ID: 11713984
[TBL] [Abstract][Full Text] [Related]
30. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
Nauck MA; Quast DR; Wefers J; Pfeiffer AFH
Diabetes Obes Metab; 2021 Sep; 23 Suppl 3():5-29. PubMed ID: 34310013
[TBL] [Abstract][Full Text] [Related]
31. Incretin hormones and type 2 diabetes.
Nauck MA; Müller TD
Diabetologia; 2023 Oct; 66(10):1780-1795. PubMed ID: 37430117
[TBL] [Abstract][Full Text] [Related]
32. Gut peptides and type 2 diabetes mellitus treatment.
Ahrén B
Curr Diab Rep; 2003 Oct; 3(5):365-72. PubMed ID: 12975025
[TBL] [Abstract][Full Text] [Related]
33. The biology of incretin hormones.
Drucker DJ
Cell Metab; 2006 Mar; 3(3):153-65. PubMed ID: 16517403
[TBL] [Abstract][Full Text] [Related]
34. Incretins, insulin secretion and Type 2 diabetes mellitus.
Vilsbøll T; Holst JJ
Diabetologia; 2004 Mar; 47(3):357-366. PubMed ID: 14968296
[TBL] [Abstract][Full Text] [Related]
35. Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus.
Meier JJ; Gallwitz B; Nauck MA
BioDrugs; 2003; 17(2):93-102. PubMed ID: 12641488
[TBL] [Abstract][Full Text] [Related]
36. Incretins: their physiology and application in the treatment of diabetes mellitus.
Tasyurek HM; Altunbas HA; Balci MK; Sanlioglu S
Diabetes Metab Res Rev; 2014 Jul; 30(5):354-71. PubMed ID: 24989141
[TBL] [Abstract][Full Text] [Related]
37. Extrapancreatic effects of GIP and GLP-1.
Vella A; Rizza RA
Horm Metab Res; 2004; 36(11-12):830-6. PubMed ID: 15655715
[TBL] [Abstract][Full Text] [Related]
38. Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.
Liu X; Harada N; Yamane S; Kitajima L; Uchida S; Hamasaki A; Mukai E; Toyoda K; Yamada C; Yamada Y; Seino Y; Inagaki N
Life Sci; 2009 Jun; 84(25-26):876-81. PubMed ID: 19358859
[TBL] [Abstract][Full Text] [Related]
39. Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility.
Miki T; Minami K; Shinozaki H; Matsumura K; Saraya A; Ikeda H; Yamada Y; Holst JJ; Seino S
Diabetes; 2005 Apr; 54(4):1056-63. PubMed ID: 15793244
[TBL] [Abstract][Full Text] [Related]
40. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs.
Deacon CF; Wamberg S; Bie P; Hughes TE; Holst JJ
J Endocrinol; 2002 Feb; 172(2):355-62. PubMed ID: 11834453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
